PMID- 37920437
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 26
IP  - 6
DP  - 2023 Dec
TI  - A retrospective study of transarterial chemoembolization (TACE) combined with 
      lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular 
      carcinoma.
PG  - 507
LID - 10.3892/ol.2023.14094 [doi]
LID - 507
AB  - The present study aimed to compare the efficacy and safety of combination therapy 
      with lenvatinib (Len) plus transarterial chemoembolization (TACE) and TACE alone 
      in patients with Barcelona Clinic Liver Cancer (BCLC) B2 stage hepatocellular 
      carcinoma (HCC). A total of 66 patients with BCLC B2 stage HCC were 
      retrospectively reviewed in the present study, of which 34 patients received Len 
      + TACE, while 32 patients received TACE alone between May 2018 and May 2020. 
      Survival outcome, tumor response and adverse events (AEs) were compared between 
      the two treatment groups. The 6-month, 1- and 2-year overall survival (OS) rates 
      were significantly higher in the Len + TACE group (97.1, 85.3 and 76.3%, 
      respectively) compared with those in the TACE group [(93.8, 81.1 and 45.4%, 
      respectively); hazard ratio (HR), 0.395; 95% confidence interval (CI), 
      0.180-0.867; P=0.023], but no significant difference in progression-free survival 
      rate was observed between the two groups (HR, 0.815; 95% CI, 0.437-1.520; 
      P=0.510). Patients receiving Len + TACE demonstrated a higher objective response 
      rate compared with those receiving TACE alone (64.7 vs. 34.4%; P=0.014). 
      Therefore, Len + TACE combination therapy was associated with increased OS and 
      tumor response compared with that of TACE monotherapy in patients with BCLC B2 
      stage HCC. However, large-scale, multicenter, prospective studies are needed to 
      further confirm these results.
CI  - Copyright: (c) Liu et al.
FAU - Liu, Junning
AU  - Liu J
AD  - Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, Sichuan 637000, P.R. China.
FAU - Yan, Shu
AU  - Yan S
AD  - Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, Sichuan 637000, P.R. China.
FAU - Zhang, Guangnian
AU  - Zhang G
AD  - Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, Sichuan 637000, P.R. China.
FAU - Yang, Linfeng
AU  - Yang L
AD  - Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, Sichuan 637000, P.R. China.
FAU - Wei, Song
AU  - Wei S
AD  - Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, Sichuan 637000, P.R. China.
FAU - Yi, Pengsheng
AU  - Yi P
AD  - Department of Hepato-Biliary-Pancreas II, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong, Sichuan 637000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20231010
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC10618929
OTO - NOTNLM
OT  - Barcelona Clinic Liver Cancer B2
OT  - combination therapy
OT  - hepatocellular carcinoma
OT  - lenvatinib
OT  - transarterial chemoembolization
COIS- The authors declare that they have no competing interests.
EDAT- 2023/11/03 06:44
MHDA- 2023/11/03 06:45
PMCR- 2023/10/10
CRDT- 2023/11/03 03:55
PHST- 2023/04/05 00:00 [received]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2023/11/03 06:45 [medline]
PHST- 2023/11/03 06:44 [pubmed]
PHST- 2023/11/03 03:55 [entrez]
PHST- 2023/10/10 00:00 [pmc-release]
AID - OL-26-6-14094 [pii]
AID - 10.3892/ol.2023.14094 [doi]
PST - epublish
SO  - Oncol Lett. 2023 Oct 10;26(6):507. doi: 10.3892/ol.2023.14094. eCollection 2023 
      Dec.